S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB. (23rd June 2022)

• Record Type: Journal Article
• Authors: van de Donk, N. W.; Bahlis, N.; Mateos, M.-V.; Weisel, K.; Dholaria, B.; Garfall, A. L.; Goldschmidt, H.; Martin, T. G.; Morillo, D.; Reece, D. E.; Hurd, D.; Rodríguez-Otero, P.; Bhutani, M.; D'Souza, A.; Oriol, A.; Askari, E.; San-Miguel, J. F.; Kortüm, K. M.; Vishwamitra, D.; Xin Wang Lin, S.; Prior, T. J.; Vandenberk, L.; Smit, M.-A. D.; Goldberg, J. D.; Wäsch, R.; Chari, A.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 84
• Page End: 85
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000843624.82943.92
• Languages: English
• ISSNs: 2572-9241